Spyre Therapeutics, Inc. Common Stock (SYRE) Financials
Key financial figures for Spyre Therapeutics, Inc. Common Stock (Q1 2026).
- Revenue
- $0
- Net Income
- -$69M
- EPS
- $-0.89
- Total Assets
- $764M
- Operating Cash Flow
- -$57M
Full income statement, balance sheet, and cash flow for Spyre Therapeutics, Inc. Common Stock on SentiSense.